Lisa Force, MD, MPH, is an Assistant Professor in Health Metrics Sciences at the Institute for Health Metrics and Evaluation (IHME) and an Assistant Professor in the Department of Pediatrics, Division of Pediatric Hematology/Oncology, at the University of Washington School of Medicine. At IHME, she leads cancer modeling for the institute’s Global Burden of Disease (GBD) Study and her research interests include global pediatric oncology, global cancer epidemiology, and cancer disparities. She believes in health equity and cultural humility.
Dr. Force earned her undergraduate degree at the University of Oregon, her medical degree at the Boston University School of Medicine, and her MPH degree with a focus in epidemiology from the Harvard T.H. Chan School of Public Health. She completed a clinical residency in Pediatrics at the University of Washington/Seattle Children’s Hospital (UW/SCH) and fellowships in Pediatric Hematology/Oncology and Global Pediatric Medicine at St. Jude Children's Research Hospital. She has previously worked clinically caring for children with cancer, blood disorders, and HIV in Botswana and is currently an attending physician in Pediatric Hematology/Oncology at Seattle Children's Hospital.
IHME was established at the University of Washington in Seattle in 2007. Its mission is to deliver to the world timely, relevant, and scientifically valid evidence to improve health policy and practice.
GBD 2019 Indonesia Subnational Collaborators. The state of health in Indonesia’s provinces, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. The Lancet Global Health. 11 October 2022. doi: 10.1016/S2214-109X(22)00371-0.
GBD 2019 Cancer Risk Factor Collaborators. The global burden of cancer attributable to risk factors, 2010–19: a systematic analysis for the Global Burden of Disease Study 2019. The Lancet. 18 August 2022. doi:
Global Burden of Disease 2019 Cancer Collaboration. Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life Years for 29 Cancer Groups From 2010 to 2019. JAMA Oncology. 30 December 2021. doi: 10.1001/jamaoncol.2021.6987.
GBD 2019 Adolescent Young Adult Cancer Collaborators. The global burden of adolescent and young adult cancer in 2019: a systematic analysis for the Global Burden of Disease Study 2019. The Lancet Oncology. 03 December 2021. doi: 10.1016/S1470-2045(21)00581-7.
GBD 2019 Respiratory Tract Cancers Collaborators. Global, regional, and national burden of respiratory tract cancers and associated risk factors from 1990 to 2019: a systematic analysis for the Global Burden of Disease Study 2019. The Lancet Respiratory Medicine. 16 August 2021. doi: 10.1016/S2213-2600(21)00164-8.
Bosetti C, Traini E, Alam T, Allen CA, Carreras G, Compton K, Fitzmaurice C, Force LM, Gallus S, Gorini G, harvey JD, Kocarnik JM, La Vecchia C, Lugo A, Naghavi M, Pennini A, Piccinelli C, Ronfani L, Xu R, Monasta L. National burden of cancer in Italy, 1990–2017: a systematic analysis for the global burden of disease study 2017. Scientific Reports. 16 December 2020. doi: 10.1038/s41598-020-79176-3.
GBD 2017 Colorectal Cancer Collaborators. The global, regional, and national burden of colorectal cancer and its attributable risk factors in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. The Lancet Gastroenterology & Hepatology. 21 October 2019. doi:10.1016/S2468-1253(19)30345-0.
Global Burden of Disease Cancer Collaboration. Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2017. JAMA Oncology. 27 September 2019;5(12):1-21. doi:10.1001/jamaoncol.2019.2996.